Evaluation of Valsartan-Sacubitril for Heart Failure in Thi Qar Patients / Iraq


  • Nagham Yahya Ghafil * Kufa University / Faculty of Pharmacy
  • Zainab Abbas Hasan Manshad Al-Hussein Teaching Hospital / Thi-Qar Health Directorate


Heart failure, Angiotensin Receptor-Neprilysin Inhibitor (ARNI), sacubitril/valsartan(ARNI), ejection fraction


Heart failure (HF) is defined as any structural and/or functional impairment of cardiac blood ejection raised from a
structural or functional cardiac disorders that impair the ability of the ventricle to fill with or eject blood, leads to a
complex clinical syndrome with typical symptoms and clinical signs1,2. HF influences 23-26 million patients
globally.4,5 The major causes of HF include ischemic heart disease (IHD) ,myocardial infarction (MI), hypertension,
and valvular heart disease (VHD). The association of an angiotensin II receptor antagonist and a neprilysin inhibitor
is a new actor in HF management.18
Patients and Methods:
This is an observational analytical Cohort study which has been performed in the Teaching Cardiac Center in ThiQar Governorate in Nasiriyah city in Iraq. All participants are patients who either recently diagnosed as heart failure
(6 months to 1 year) or diagnosed since (1 to 3 years). Key criteria for the study has been involved sociodemographic characteristics as age (years) (40-60 or more than 60), Body Mass Index(BMI), educational level of
patients, occupation, history of tobacco smoking or alcohol intake, the history of co-morbidities as Atrial
fibrillation (AF), Diabetes Mellitus (DM) (types I and II), Dyslipidemia, Chronic kidney disease(CKD) and Chronic
obstructive pulmonary disease(COPD).
The number of both genders is equal in my study. After 6 weeks follow up period from starting to take ARNI,
(27.02%) of them improved regarding EF. About (72.98%) of them had initial increament in ejection fraction by
about (4 -8%). Good prognosis regarding signs and symptoms of heart failure were remarkable.
- Chronic symptomatic patients with HFrEF ( NYHA class II or III ) who tolerate an ACEI or ARB can be
switched safely to sacubitril/valsartan (ARNI), to further reduce morbidity and mortality.
- The main barrier that prevents cardiologists in Thi Qar to prescribe ARNI is the cost of the drug because
most of the Iraqi patients are unable to buy this expensive medication.
1-All patients with HFrEF (NYHA class II - III) should receive ARNI.
2-This medication should be provided in all Iraqi hospitals and Cardiac centers because this drug is very expensive
and patients may not be able to buy it.
3-Explaining the concept of the medication related burden and further studies are recommended to include
adherence assessment of patients toward treatment


-Wilson S Colucci, MD (https://www.uptodate.com/contents/heart-failure-clinical-manifestations-anddiagnosis-in-adults/contributors .Heart failure: Clinical manifestations and diagnosis in adults .

-Amir Hossein Behnoush , Amirmohammad Khalaji , Nasim Naderi and others.ACC/AHA/HFSA 2022

and ESC 2021 guidelines on heart failure comparison

-Navya Sakhamuri , Sreekartthik Athiyaman , Bhawna Randhi and other. Sacubitril/Valsartan in Heart

Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away? .

-H K Chopra, G S Wander, Tiny Nair and others .Angiotensin Receptor-Neprilysin Inhibitor Therapy

and Cardiac Remodeling in Heart Failure: Consensus Statement from India.

-Joana Cabral, Henrique Vasconcelos, Paulo Maia-Araújo and others. Sacubitril/valsartan in everyday

clinical practice: an observational

study based on the experience of a heart failure clinic

-Michel Komajda, Stefan D. Anker, Martin R. Cowie and others. Physicians’ adherence to

guidelinerecommended medications in heart failure

with reduced ejection fraction: data from the QUALIFY global survey.

-Helena Norberg,Ellinor Bergdahl and Krister Lindmark.Eligibility of sacubitril–valsartan in a realworld heart failure population: a community-based single-centre study.

-Paul A. Heidenreich, Biykem Bozkurt, Vice ChairDavid Aguilar, Larry A. Allen and others. 2022

AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of

Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

-Sashiananthan Ganesananthan , Nisar Shah, Parin Shah and others. Real- world treatment switching to

sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study .

-Lindsey R. Sangaralingham,Jeson Sangaralingham,Nilay D. Shah, PhDXiaoxi Yao and others.

Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.

-Speranza Rubattu & Filippos Triposkiadis. Resetting the neurohormonal balance in heart failure

(HF):the relevance of the natriuretic peptide (NP) system to the clinicalmanagement of patients with HF.

-Mingsong Zhang , Yifei Zou , Yangxue Li and others. The history and mystery of sacubitril/valsartan:

From clinical trial to the real world.

- Domingo Pascual, Antoni Bayé, Paola Beltrán and others . Sacubitril-Valsartan, Clinical Benefits and

Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction.

-Daisuke Usuda, Toshihiro Higashikawa, Yuta Hotchi and others. Angiotensin receptor blocker

neprilysin inhibitors .

-Chan Soon Park, Jin Joo Park, Alexandre Mebazaa and others .Characteristics, Outcomes, and

Treatment of Heart Failure With

Improved Ejection Fraction.

-Nicolò Ghionzoli, Francesco Gentile , Anna Maria Del Franco and others. Current and emerging drug

targets in heart failure treatment.

-Nicolò Ghionzoli , Francesco Gentile , Anna Maria Del Franco and others. Current and emerging

drug targets in heart failure treatment

-Massimo F. Piepoli, Rizwan I. Hussain, Josep Comin-Colet and others .OUTSTEP-HF: randomised

controlled trial comparing short-term effects of 19-sacubitril/valsartan versus enalapril on daily physical

activity in patients with chronic heart failure with reduced ejection fraction .

-Rui Zhang, Xiaotong Sun, , Ya Li, MD and others . The Efficacy and Safety of Sacubitril/ Valsartan

in Heart Failure Patients .

-Helena Norberg, Ellinor Bergdahl and Krister Lindmark . Eligibility of sacubitril–valsartan in a realworld heart failure population: a community based single-centre study.

-Scott D. Solomon, Brian Claggett, Milton Packer Efficacy of Sacubitril/Valsartan Relative to a Prior

Decompensation The PARADIGM-HF Trialand others .

- Mehmet Kış, Oktay Şenöz2, Tuncay Güze and others . The Relationship Between N-Terminal ProBrain Natriuretic Peptide Level and LeftVentricular Metabolic Index inPatients with Heart Failure with

Mildly Reduced Ejection Fraction .

-Andrea Di Lenarda , Gabriele Di Gesaro , Filippo Maria Sarullo and others . Sacubitril/Valsartan in

Heart Failure with Reduced Ejection Fraction: Real World Experience from Italy (the REAL.IT Study) .

-Abdelfatah A. Elasfar , Waleed Alhabeeb , Salma Elasfar and others .Heart Failure in the Middle East

Arab Countries: Current and Future Perspectives .

-Pia M. Schumacher , Nicolas Becker, Ross T. Tsuyuki and others. The evidence for pharmacist care

in outpatients with heart failure: a systematic review and meta-analysis